2000-1996

2000 

 

Cerebrospinal fluid HIV-1 RNA during treatment with ritonavir/saquinavir or ritonavir/saquinavir/stavudine.
Gisolf EH, Enting RH, Jurriaans S, de Wolf F, van der Ende ME, Hoetelmans RM, Portegies P, Danner SA. National AIDS Therapy Evaluation Center, Amsterdam, The Netherlands.
AIDS. 2000 Jul 28;14(11):1583-9.
Link naar publicatie 
 
Declining number of patients with cryptococcosis in the Netherlands in the era of highly active antiretroviral therapy.
van Elden LJ, Walenkamp AM, Lipovsky MM, Reiss P, Meis JF, de Marie S, Dankert J, Hoepelman AI. Department of Internal Medicine, University Hospital Utrecht, The Netherlands.
AIDS. 2000 Dec 1;14(17):2787-8.
Link naar publicatie 
 
Evaluation of a second-generation nucleic acid sequence-based amplification assay for quantification of HIV type 1 RNA and the use of ultrasensitive protocol adaptations.
Notermans DW, de Wolf F, Oudshoorn P, Cuijpers HT, Pirillo M, Tiller FW, McClernon DR, Prins JM, Lange JM, Danner SA, Goudsmit J, Jurriaans S. Division of Infectious Diseases, Tropical Medicine, and AIDS and National AIDS Therapy Evaluation Center (NATEC
AIDS Res Hum Retroviruses. 2000 Oct 10;16(15):1507-17.
Link naar publicatie 
 
Once-daily dosing of saquinavir and low-dose ritonavir in HIV-1-infected individuals: a pharmacokinetic pilot study.
Van Heeswijk RP, Veldkamp AI, Mulder JW, Meenhorst PL, Lange JM, Beijnen JH, Hoetelmans RM. Department of Pharmacy and Pharmacology, Slotervaart Hospital, Amsterdam, The Netherlands.
AIDS. 2000 Jun 16;14(9):F103-10.
Link naar publicatie
 
Quality of life in asymptomatic- and symptomatic HIV infected patients in a trial of ritonavir/saquinavir therapy. The Prometheus Study Group.
Nieuwkerk PT, Gisolf EH, Colebunders R, Wu AW, Danner SA, Sprangers MA. Department of Medical Psychology, Tropical Medicine and AIDS, Academic Medical Center, University of Amsterdam, The Netherlands.
AIDS. 2000 Jan 28;14(2):181-7.
Link naar publicatie
 
Quality of life in maintenance vs prolonged induction therapy for HIV
Nieuwkerk PT, Reijers MHE, Weigel HM, Lange JMA, Sprangers MAG.
JAMA. 2000; Jul 12: Vol 284, 2.
Link naar publicatie 
 
Reduction of the HIV-1-infected T-cell reservoir by immune activation treatment is dose-dependent and restricted by the potency of antiretroviral drugs.
Fraser C, Ferguson NM, Ghani AC, Prins JM, Lange JM, Goudsmit J, Anderson RM, de Wolf F. Wellcome Trust Centre for the Epidemiology of Infectious Disease, University of Oxford, UK.
AIDS. 2000 Apr 14;14(6):659-69.
Link naar publicatie 
 
Slower decline of plasma HIV-1 RNA following highly suppressive antiretroviral therapy in primary compared with chronic infection.
Putter H, Prins JM, Jurriaans S, Roos M, Ferguson NM, van Praag R, van der Hoek L, Schuitemaker H, Anderson RM, Goudsmit J, Lange JM, de Wolf F. Department of Human Retrovirology, University of Amsterdam, The Netherlands.
AIDS. 2000 Dec 22;14(18):2831-9.
Link naar publicatie
Comment in AIDS. 2001 May 25;15(8):1087. 

Subtype-specific sequence variation of the HIV type 1 long terminal repeat and primer-binding site.
De Baar MP, De Ronde A, Berkhout B, Cornelissen M, Van Der Horn KH, Van Der Schoot AM, De Wolf F, Lukashov VV, Goudsmit J. Department of Human Retrovirology, Academic Medical Center, University of Amsterdam, The Netherlands.
AIDS Res Hum Retroviruses. 2000 Mar 20;16(5):499-504.
Link naar publicatie 
 
The effect of treatment intensification in HIV-infection: a study comparing treatment with ritonavir/saquinavir and ritonavir/saquinavir/stavudine.
Gisolf EH, Jurriaans S, Pelgrom J, van Wanzeele F, van der Ende ME, Brinkman K, Borst MJ, de Wolf F, Japour AJ, Danner SA. National AIDS Therapy Evaluation Center, Department of Internal Medicine, Academic Medical Center, Amsterdam, The Netherlands.
AIDS. 2000 Mar 10;14(4):405-13.
Link naar publicatie

 

1999 

 

Antigen-driven CD4+ T cell and HIV-1 dynamics: residual viral replication under highly active antiretroviral therapy.
Ferguson NM, de Wolf F, Ghani AC, Fraser C, Donnelly CA, Reiss P, Lange JM, Danner SA, Garnett GP, Goudsmit J, Anderson RM. Wellcome Trust Centre for the Epidemiology of Infectious Disease, University of Oxford OX1 3PS, United Kingdom.
Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15167-72.
Link naar publicatie 
 
Design and evaluation of a human immunodeficiency virus type 1 RNA assay using nucleic acid sequence-based amplification technology able to quantify both group M and O viruses by using the long terminal repeat as target.
De Baar MP, van der Schoot AM, Goudsmit J, Jacobs F, Ehren R, van der Horn KH, Oudshoorn P, de Wolf F, de Ronde A. Department of Human Retrovirology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
J Clin Microbiol. 1999 Jun;37(6):1813-8.
Link naar publicatie 
 
Detection of human immunodeficiency virus type 1 nucleocapsid protein p7 in vitro and in vivo.
De Baar MP, van der Horn KH, Goudsmit J, de Ronde A, de Wolf F. University of Amsterdam, Department of Human Retrovirology, Academic Medical Centre, Amsterdam, The Netherlands.
J Clin Microbiol. 1999 Jan;37(1):63-7.
Link naar publicatie 
 
Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy.
Prins JM, Jurriaans S, van Praag RM, Blaak H, van Rij R, Schellekens PT, ten Berge IJ, Yong SL, Fox CH, Roos MT, de Wolf F, Goudsmit J, Schuitemaker H, Lange JM. Department of Internal Medicine, Tropical Medicine, and AIDS, Academic Medical Center, Unive
AIDS. 1999 Dec 3;13(17):2405-10.
Link naar publicatie 
 
Incidence of discontinuation of highly active antiretroviral combination therapy (HAART) and its determinants.
Van Roon EN, Verzijl JM, Juttmann JR, Lenderink AW, Blans MJ, Egberts AC. Hospital Pharmacy Midden-Brabant, TweeSteden Hospital, Tilburg, The Netherlands.
J Acquir Immune Defic Syndr Hum Retrovirol. 1999; Mar 1: Vol 20(3):290-4.
Link naar publicatie 
 
Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs.
De Jong JJ, Goudsmit J, Lukashov VV, Hillebrand ME, Baan E, Huismans R, Danner SA, ten Veen JH, de Wolf F, Jurriaans S. Department of Human Retrovirology, Academic Medical Centre, University of Amsterdam, The Netherlands.
AIDS. 1999 Jan 14;13(1):75-80.
Link naar publicatie 
 
Ongoing HIV dissemination during HAART
Grossman Z, Polis M, Feinberg MB, Grossman Z, Levi I, Jankelevich S, Yarchoan R, Boon J, de Wolf F, Lange JM, Goudsmit J, Dimitrov DS, Paul WE. Office of AIDS Research, National Institutes of Health, Bethesda, Maryland, USA.
Nat Med. 1999 Oct;5(10):1099-104.
Link naar publicatie 
 
Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons.
Wit FW, van Leeuwen R, Weverling GJ, Jurriaans S, Nauta K, Steingrover R, Schuijtemaker J, Eyssen X, Fortuin D, Weeda M, de Wolf F, Reiss P, Danner SA, Lange JM. National AIDS Therapy Evaluation Center (NATEC), Department of Infectious Diseases, Tropical
J Infect Dis. 1999 Apr;179(4):790-8.
Link naar publicatie

 

1998 

 

A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study.
Montaner JS, Reiss P, Cooper D, Vella S, Harris M, Conway B, Wainberg MA, Smith D, Robinson P, Hall D, Myers M, Lange JM. Canadian HIV Trials Network, St Paul's Hospital/University of British Colombia, Vancouver.
JAMA. 1998 Mar 25;279(12):930-7.
Link naar publicatie
Comment in: ACP J Club. 1998 Sep-Oct;129(2):42. JAMA. 1998 Mar 25;279(12):957-9. JAMA. 1999 Jan 13;281(2):130-1. JAMA. 1999 Jan 13;281(2):130; author reply 131. 

AIDS: new developments. VI. HIV reservoirs during intensive antiretroviral treatment [Article in Dutch]

Notermans DW, Danner SA, de Wolf F, Lange JM. Afd. Algemene Inwendige Geneeskunde, onderafd, Infectieziekten, Tropische geneeskunde en AIDS, Academisch Medisch Centrum, Amsterdam.
Ned Tijdschr Geneeskd. 1998 Aug 22;142(34):1909-12.
Link naar publicatie 
 
Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy.
Weverling GJ, Lange JM, Jurriaans S, Prins JM, Lukashov VV, Notermans DW, Roos M, Schuitemaker H, Hoetelmans RM, Danner SA, Goudsmit J, de Wolf F. National AIDS Therapy Evaluation Centre, Department of Internal Medicine, University of Amsterdam, The Neth
AIDS. 1998 Jul 30;12(11):F117-22.
Link naar publicatie 
 
Amsterdam duration of antiretroviral medication (ADAM)--study: induction-suppression treatment in HIV-I infection, preliminary results [Article in Dutch]
Reijers MH, Weverling GJ, Jurriaans S, Wit FW, van Leeuwen R, Bruisten SM, Frissen PH, Weigel HM, Mulder JW, ten Kate RW, de Wolf F, Schuitemaker H, Lange JM.
Ned Tijdschr Geneeskd. 1998 Oct 3;142(40):2230. 
 
An open randomized controlled trial of zidovudine plus lamivudine versus stavudine plus lamivudine.
Foudraine NA, de Jong JJ, Jan Weverling G, van Benthem BH, Maas J, Keet IP, Jurriaans S, Roos MT, Vandermeulen K, de Wolf F, Lange JM. Department of Public Health and Environment, Academic Medical Centre, University of Amsterdam, The Netherlands.
AIDS. 1998 Aug 20;12(12):1513-9.
Link naar publicatie 
 
Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation.
Pakker NG, Notermans DW, de Boer RJ, Roos MT, de Wolf F, Hill A, Leonard JM, Danner SA, Miedema F, Schellekens PT. Department of Clinical Viro-Immunology, Central Laboratory of The Netherlands Red Cross Blood Transfusion Service, Amsterdam.
Nat Med. 1998 Feb;4(2):208-14. 
Comment in: Nat Med. 1998 Feb;4(2):145-6. 

Body mass index course in asymptomatic HIV-infected homosexual men and the predictive value of a decrease of body mass index for progression to AIDS.
Maas JJ, Dukers N, Krol A, van Ameijden EJ, van Leeuwen R, Roos MT, de Wolf F, Coutinho RA, Keet IP. Municipal Health Service, Department of Public Health and Environment, Amsterdam, The Netherlands.
J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Nov 1;19(3):254-9.
Link naar publicatie 
 
Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine.
Foudraine NA, Hoetelmans RM, Lange JM, de Wolf F, van Benthem BH, Maas JJ, Keet IP, Portegies P. Department of Public Health and Environment, Amsterdam, Netherlands.
Lancet. 1998 May 23;351(9115):1547-51.
Link naar publicatie
Comment in: Lancet. 1998 Aug 1;352(9125):402. Lancet. 1998 Aug 1;352(9125):402-3. 

Decrease of HIV-1 RNA levels in lymphoid tissue and peripheral blood during treatment with ritonavir, lamivudine and zidovudine. Ritonavir/3TC/ZDV Study Group.
Notermans DW, Jurriaans S, de Wolf F, Foudraine NA, de Jong JJ, Cavert W, Schuwirth CM, Kauffmann RH, Meenhorst PL, McDade H, Goodwin C, Leonard JM, Goudsmit J, Danner SA. Division of Infectious Diseases, Tropical Medicine and AIDS and National AIDS Ther
AIDS. 1998 Jan 22;12(2):167-73.
Link naar publicatie 
 
Emergence of syncytium-inducing human immunodeficiency virus type 1 variants coincides with a transient increase in viral RNA level and is an independent predictor for progression to AIDS.
Spijkerman I, de Wolf F, Langendam M, Schuitemaker H, Coutinho R. Division of Public Health and Environment, Municipal Health Service, Amsterdam, The Netherlands.
J Infect Dis. 1998 Aug;178(2):397-403.
Link naar publicatie 
 
Improvement of chronic diarrhoea in patients with advanced HIV-1 infection during potent antiretroviral therapy.
Foudraine NA, Weverling GJ, van Gool T, Roos MT, de Wolf F, Koopmans PP, van den Broek PJ, Meenhorst PL, van Leeuwen R, Lange JM, Reiss P. Municipal Health Service, Department of Public Health and Environment, Amsterdam, The Netherlands.
AIDS. 1998 Jan 1;12(1):35-41.
Link naar publicatie 

In vitro replication kinetics of human immunodeficiency virus type 1 (HIV-1) variants in relation to virus load in long-term survivors of HIV-1 infection.
Blaak H, Brouwer M, Ran LJ, de Wolf F, Schuitemaker H. Department of Clinical Viro-Immunology, Central Laboratory of The Netherlands Red Cross Blood Transfusion Service, University of Amsterdam.
J Infect Dis. 1998 Mar;177(3):600-10.
Link naar publicatie 
 
Longitudinal analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte responses: a predominant gag-specific response is associated with nonprogressive infection.
Pontesilli O, Klein MR, Kerkhof-Garde SR, Pakker NG, de Wolf F, Schuitemaker H, Miedema F. Department of Clinical Viro-Immunology, Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Amsterdam, The Netherlands.
J Infect Dis. 1998 Oct;178(4):1008-18.
Link naar publicatie 
 
Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapy.
Burger DM, Hoetelmans RM, Hugen PW, Mulder JW, Meenhorst PL, Koopmans PP, Brinkman K, Keuter M, Dolmans W, Hekster YA. Department of Clinical Pharmacy, University Hospital Nijmegen, The Netherlands.
Antivir Ther. 1998; Vol 3(4):215-20. 
 
Low T-cell responses to CD3 plus CD28 monoclonal antibodies are predictive of development of AIDS.
Roos MT, Prins M, Koot M, de Wolf F, Bakker M, Coutinho RA, Miedema F, Schellekens PT. Department of Clinical Viro-Immunology, Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Academic Medical Centre, University of Amsterdam.
AIDS. 1998 Oct 1;12(14):1745-51.
Link naar publicatie 
 
Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study.
Reijers MH, Weverling GJ, Jurriaans S, Wit FW, Weigel HM, Ten Kate RW, Mulder JW, Frissen PH, van Leeuwen R, Reiss P, Schuitemaker H, de Wolf F, Lange JM. Department of Internal Medicine, National AIDS Therapy Evaluation Centre, Academic Medical Centre, 
Lancet. 1998 Jul 18;352(9123):185-90.
Link naar publicatie
Comment in: ACP J Club. 1999 Jan-Feb;130(1):14. Lancet. 1998 Oct 3;352(9134):1149 

Rate of HIV-1 decline following antiretroviral therapy is related to viral load at baseline and drug regimen.
Notermans DW, Goudsmit J, Danner SA, de Wolf F, Perelson AS, Mittler J. Department of Human Retrovirology, University of Amsterdam, The Netherlands.
AIDS. 1998 Aug 20;12(12):1483-90.
Link naar publicatie
Comment in: AIDS. 1999 Feb 25;13(3):429-30. 

The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy.
Hoetelmans RM, Reijers MH, Weverling GJ, ten Kate RW, Wit FW, Mulder JW, Weigel HM, Frissen PH, Roos M, Jurriaans S, Schuitemaker H, de Wolf F, Beijnen JH, Lange JM. Department of Pharmacy and Pharmacology, Slotervaart Hospital, Amsterdam, The Netherland
AIDS. 1998 Jul 30;12(11):F111-5.
Link naar publicatie 
 
Treatment of AIDS-related non-Hodgkin's lymphoma with chemotherapy (CNOP) and r-hu-G-CSF: clinical outcome and effect on HIV-1 viral load.
Kersten MJ, Verduyn TJ, Reiss P, Evers LM, de Wolf F, van Oers MH. Department of Hematology, Academic Medical Center, Amsterdam, The Netherlands.
Ann Oncol. 1998 Oct;9(10):1135-8.
Link naar publicatie 
 
Virological evaluation of treating HIV-infected patients with (combinations of) antiretroviral drugs at the Amsterdam Academic Medical Center, 1996/'97 [Article in Dutch]
De Wolf F, de Jong JJ, Hertogs K, Danner SA, Lange JM, Goudsmit J. Academisch Medisch Centrum, Amsterdam.
Ned Tijdschr Geneeskd. 1998 Mar 14;142(11):573-8.
Link naar publicatie
Comment in: Ned Tijdschr Geneeskd. 1998 May 16;142(20):1169-70

 

1997 

 

AIDS prognosis based on HIV-1 RNA, CD4+ T-cell count and function: markers with reciprocal predictive value over time after seroconversion.
De Wolf F, Spijkerman I, Schellekens PT, Langendam M, Kuiken C, Bakker M, Roos M, Coutinho R, Miedema F, Goudsmit J. Department of Human Retrovirology, University of Amsterdam, The Netherlands.
AIDS. 1997 Dec;11(15):1799-806.
Link naar publicatie 
 
AIDS; new developments. III. Predictive value of the quantity of HIV-RNA for the course of the HIV infection and the effect of the treatment [Article in Dutch]
De Wolf F, Goudsmit J. Academisch Medisch Centrum, afd. Humane Retrovirologie, Amsterdam.
Ned Tijdschr Geneeskd. 1997 May 24;141(21):1043-50.
Link naar publicatie 
 
Association between CCR5 genotype and the clinical course of HIV-1 infection.
De Roda Husman AM, Koot M, Cornelissen M, Keet IP, Brouwer M, Broersen SM, Bakker M, Roos MT, Prins M, de Wolf F, Coutinho RA, Miedema F, Goudsmit J, Schuitemaker H. Central Laboratory of the Red Cross Blood Transfusion Service, University of Amsterdam A
Ann Intern Med. 1997 Nov 15;127(10):882-90.
Link naar publicatie
Comment in: Ann Intern Med. 1998 May 1;128(9):780. 

Early and late HIV-1 RNA level and its association with other markers and disease progression in long-term AIDS-free homosexual men.
Spijkerman IJ, Prins M, Goudsmit J, Veugelers PJ, Coutinho RA, Miedema F, de Wolf F. Division of Public Health and Environment, University of Amsterdam, The Netherlands.
AIDS. 1997 Sep;11(11):1383-8.
Link naar publicatie 
 
Gag-specific immune responses after immunization with p17/p24: Ty virus-like particles in HIV type 1-seropositive individuals.
Klein MR, Veenstra J, Holwerda AM, Roos MT, Gow I, Patou G, Coutinho RA, De Wolf F, Miedema F. Department of Clinical Viro-Immunology, Central Laboratory of The Netherlands Red Cross Blood Transfusion Service, Amsterdam, The Netherlands.
AIDS Res Hum Retroviruses. 1997 Mar 20;13(5):393-9. 
 
High-dose interferon-alpha2a exerts potent activity against human immunodeficiency virus type 1 not associated with antitumor activity in subjects with Kaposi's sarcoma.
Frissen PH, de Wolf F, Reiss P, Bakker PJ, Veenhof CH, Danner SA, Goudsmit J, Lange JM. Division of Infectious Diseases, Tropical Medicine, and AIDS, Academic Medical Center, University of Amsterdam, The Netherlands.
J Infect Dis. 1997 Sep;176(3):811-4.
Link naar publicatie 
Pagina met onderzoek

Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS.
Van Baalen CA, Pontesilli O, Huisman RC, Geretti AM, Klein MR, de Wolf F, Miedema F, Gruters RA, Osterhaus AD. Institute of Virology, Erasmus University Rotterdam, The Netherlands.
J Gen Virol. 1997 Aug;78 ( Pt 8):1913-8.
Link naar publicatie 
 
Kinetics of immune functions and virus replication during HIV-1 infection.
Pontesilli O, Klein MR, Kerkhof-Garde SR, Pakker NG, de Wolf F, Schuitemaker H, Miedema F. Department Clinical Viro-Immunology, Central Laboratory of The Netherlands Red Cross Blood Transfusion Service, University of Amsterdam, The Netherlands.
Immunol Lett. 1997 Jun 1;57(1-3):125-30. 
 
Longitudinal analysis of CD4 T cell counts, T cell reactivity, and human immunodeficiency virus type 1 RNA levels in persons remaining AIDS-free despite CD4 cell counts less 200 for more then 5 years.
Keet IP, Janssen M, Veugelers PJ, Miedema F, Klein MR, Goudsmit J, Coutinho RA, de Wolf F. Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, and Department of Virology, University of Amsterdam.
J Infect Dis. 1997 Sep;176(3):665-71.
Link naar publicatie 
 
Overshoot of HIV-1 viraemia after early discontinuation of antiretroviral treatment.
De Jong MD, de Boer RJ, de Wolf F, Foudraine NA, Boucher CA, Goudsmit J, Lange JM. Department of Internal Medicine, University of Amsterdam, The Netherlands.
AIDS. 1997 Sep;11(11):F79-84.
Link naar publicatie 
 
Risk of iatrogenic human immunodeficiency virus infection through transfusion of blood tested by inappropriately stored or expired rapid antibody assays in a Zambian hospital.
Consten EC, van der Meer JT, de Wolf F, Heij HA, Henny PC, van Lanschot JJ. Department of Surgery, Academic Medical Centre, Amsterdam, The Netherlands.
Transfusion. 1997 Sep;37(9):930-4.
Link naar publicatie 
 
Selective inhibition of syncytium-inducing and nonsyncytium-inducing HIV-1 variants in individuals receiving didanosine or zidovudine, respectively.
Van't Wout AB, Ran LJ, de Jong MD, Bakker M, van Leeuwen R, Notermans DW, Loeliger AE, de Wolf F, Danner SA, Reiss P, Boucher CA, Lange JM, Schuitemaker H. Department of Clinical Viro-Immunology, Central Laboratory of the Netherlands Red Cross Blood Tran
J Clin Invest. 1997 Nov 1;100(9):2325-3
Link naar publicatie 
 
Temporal relationship between human immunodeficiency virus type 1 RNA levels in serum and cellular infectious load in peripheral blood.
Blaak H, de Wolf F, van 't Wout AB, Pakker NG, Bakker M, Goudsmit J, Schuitemaker H. Department of Clinical Viro-Immunology, Central Laboratory of The Netherlands Red Cross Blood Transfusion Service, University of Amsterdam.
J Infect Dis. 1997 Nov;176(5):1383-7.
Link naar publicatie 
 
Zidovudine-resistant HIV strains in untreated intravenous drug users and homosexual men in Amsterdam infected in 1996 [Article in Dutch]
de Jong JJ, Jurriaans S, Coutinho RA, de Wolf F, Goudsmit J. Academisch Medisch Centrum, afd. Humane Retrovirologie, Amsterdam.
Ned Tijdschr Geneeskd. 1997 Oct 18;141(42):2030-1.
Link naar publicatie

 

1996 

 

Decline of HIV-1 RNA in cerebrospinal fluid during zidovudine treatment.
Portegies P, Danner SA, Enting RH, Meilof J, de Wolf F, Goudsmit J
Antivir Ther. 1996 Aug;1(3):195. 
 
Predictors for non- and slow progression in human immunodeficiency virus (HIV) type 1 infection: low viral RNA copy numbers in serum and maintenance of high HIV-1 p24-specific but not V3-specific antibody levels.
Hogervorst E, Jurriaans S, de Wolf F, van Wijk A, Wiersma A, Valk M, Roos M, van Gemen B, Coutinho R, Miedema F, et al. Human Retrovirus Laboratory, University of Amsterdam, Netherlands.
J Infect Dis. 1995 Apr;171(4):811-21. 
 
Replication of a pre-existing resistant HIV-1 subpopulation in vivo after introduction of a strong selective drug pressure.
De Jong MD, Schuurman R, Lange JM, Boucher CA. Department of Virology, Academic Medical Centre, University of Amsterdam, The Netherlands.
Antivir Ther. 1996 Jan;1(1):33-41. 
 
T cell telomere length in HIV-1 infection: no evidence for increased CD4+ T cell turnover.
Wolthers KC, Bea G, Wisman A, Otto SA, de Roda Husman AM, Schaft N, de Wolf F, Goudsmit J, Coutinho RA, van der Zee AG, Meyaard L, Miedema F. Department of Clinical Viro-Immunology, Central Laboratory of the Netherlands Red Cross Blood Transfusion Servic
Science. 1996 Nov 29;274(5292):1543-7.
Link naar publicatie

 

 
 

Stichting HIV Monitoring

Stichting HIV Monitoring (SHM) levert een belangrijke en noodzakelijke bijdrage aan de zorg voor mensen met hiv in Nederland. Door middel van het verzamelen en bewerken van gecodeerde data van hiv-positieve personen uit het hele land draagt ons monitor-onderzoek structureel bij aan de kennis over hiv en stelt het behandelend artsen in staat om de zorg voor hun patiënten continu te verbeteren. Ons jaarlijkse Monitoring Report geeft waardevolle input voor het ontwikkelen van hiv-zorg en preventiebeleid in Nederland en binnen de Europese Unie.

Bezoekadres

Nicolaes Tulphuis
Tafelbergweg 51
1105 BD Amsterdam

Postadres

Academisch Medisch Centrum
Universiteit van Amsterdam
Meibergdreef 9 1105 AZ Amsterdam

© Stichting HIV Monitoring  | Disclaimer  | Colofon